Definium's LSD drug clears bar in first of two Phase 3 anxiety disorder trials
Definium Therapeutics said Wednesday its oral LSD candidate has passed a late-stage study in generalized anxiety disorder (GAD), not even two months after reporting trial success for the same asset in a severe form of ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.